Factors associated with improved DpR in the final multiple regression model were panitumumab treatment (vs. bevacizumab), liver-only metastatic disease (vs. liver + other or other only metastases), WT BRAF status (vs. mutant) and age (decreased vs. increased, continuous variable) (Table 2b). Here, BRAF is linked to metastatic neoplasm.